S&P 500   5,100.95 (+0.09%)
DOW   38,959.26 (-0.10%)
QQQ   439.60 (+0.14%)
NIO   5.82 (+1.22%)
BABA   74.52 (+0.66%)
T   16.87 (-0.35%)
GE   156.51 (-0.24%)
DIS   111.66 (+0.07%)
AMC   4.35 (+0.69%)
XOM   105.40 (+0.84%)
S&P 500   5,100.95 (+0.09%)
DOW   38,959.26 (-0.10%)
QQQ   439.60 (+0.14%)
NIO   5.82 (+1.22%)
BABA   74.52 (+0.66%)
T   16.87 (-0.35%)
GE   156.51 (-0.24%)
DIS   111.66 (+0.07%)
AMC   4.35 (+0.69%)
XOM   105.40 (+0.84%)
S&P 500   5,100.95 (+0.09%)
DOW   38,959.26 (-0.10%)
QQQ   439.60 (+0.14%)
NIO   5.82 (+1.22%)
BABA   74.52 (+0.66%)
T   16.87 (-0.35%)
GE   156.51 (-0.24%)
DIS   111.66 (+0.07%)
AMC   4.35 (+0.69%)
XOM   105.40 (+0.84%)
S&P 500   5,100.95 (+0.09%)
DOW   38,959.26 (-0.10%)
QQQ   439.60 (+0.14%)
NIO   5.82 (+1.22%)
BABA   74.52 (+0.66%)
T   16.87 (-0.35%)
GE   156.51 (-0.24%)
DIS   111.66 (+0.07%)
AMC   4.35 (+0.69%)
XOM   105.40 (+0.84%)

EyePoint Pharmaceuticals (EYPT) News Today

$28.11
+0.90 (+3.31%)
(As of 08:56 AM ET)
SourceHeadline
marketbeat.com logoUBS Group AG Acquires 437,190 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
marketbeat.com - March 1 at 4:28 AM
finance.yahoo.com logoEyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024
finance.yahoo.com - February 29 at 7:16 AM
globenewswire.com logoEyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024
globenewswire.com - February 29 at 7:00 AM
marketbeat.com logoEyePoint Pharmaceuticals (NASDAQ:EYPT) Sees Unusually-High Trading Volume
marketbeat.com - February 27 at 12:31 PM
globenewswire.com logoEyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
globenewswire.com - February 27 at 7:00 AM
marketbeat.com logoBarclays PLC Acquires 23,208 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
marketbeat.com - February 27 at 4:16 AM
MarketBeat logoEyePoint Pharmaceuticals (NASDAQ:EYPT) Trading 6.4% Higher
americanbankingnews.com - February 25 at 4:12 AM
finance.yahoo.com logoEYPT Jul 2024 30.000 put
finance.yahoo.com - February 23 at 1:48 AM
benzinga.com logoEyePoint Pharmaceuticals Stock (NASDAQ:EYPT), Short Interest Report
benzinga.com - February 22 at 8:47 PM
marketbeat.com logoHighTower Advisors LLC Sells 45,832 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
marketbeat.com - February 22 at 4:48 AM
MarketBeat logoEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Consensus Rating of "Buy" from Analysts
americanbankingnews.com - February 22 at 1:20 AM
finance.yahoo.com logoEYPT May 2024 30.000 put
finance.yahoo.com - February 21 at 3:50 PM
seekingalpha.com logoEyePoint Is Betting The Bank On EYP-1901
seekingalpha.com - February 21 at 8:36 AM
seekingalpha.com logoEyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time
seekingalpha.com - February 20 at 1:50 PM
finance.yahoo.com logoEYPT Mar 2024 40.000 call
finance.yahoo.com - February 17 at 8:40 AM
finance.yahoo.com logoEYPT Mar 2024 25.000 put
finance.yahoo.com - February 17 at 8:40 AM
investorplace.com logoThe 3 Most Promising Stocks to Invest in Before They Take Off
investorplace.com - February 17 at 12:40 AM
marketbeat.com logoEyePoint Pharmaceuticals (NASDAQ:EYPT) Price Target Increased to $39.00 by Analysts at Mizuho
marketbeat.com - February 16 at 7:39 PM
markets.businessinsider.com logoAnalysts Offer Insights on Healthcare Companies: SAGE Therapeutics (SAGE) and EyePoint Pharmaceuticals (EYPT)
markets.businessinsider.com - February 16 at 12:55 PM
globenewswire.com logoEyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com - February 16 at 7:00 AM
finance.yahoo.com logoAre You Looking for a Top Momentum Pick? Why EyePoint Pharmaceuticals (EYPT) is a Great Choice
finance.yahoo.com - February 15 at 3:41 PM
finance.yahoo.com logoHere's What Could Help EyePoint Pharmaceuticals (EYPT) Maintain Its Recent Price Strength
finance.yahoo.com - February 13 at 4:23 PM
finance.yahoo.com logoWall Street Analysts Think EyePoint Pharmaceuticals (EYPT) Could Surge 31.27%: Read This Before Placing a Bet
finance.yahoo.com - February 13 at 4:23 PM
marketbeat.com logoEyePoint Pharmaceuticals (NASDAQ:EYPT) Trading 2.4% Higher
marketbeat.com - February 13 at 1:32 PM
marketbeat.com logoEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Stock Holdings Raised by Jump Financial LLC
marketbeat.com - February 12 at 4:36 AM
msn.com logoInsider Buying at These Biotechs Is Huge
msn.com - February 5 at 7:00 PM
markets.businessinsider.com logoEyePoint Pharmaceuticals Earns Buy Rating Following Promising EYP-1901 Clinical Trial Results
markets.businessinsider.com - February 5 at 2:00 PM
marketbeat.com logoEyePoint Pharmaceuticals (NASDAQ:EYPT) Sets New 12-Month High at $29.48
marketbeat.com - February 5 at 9:54 AM
finance.yahoo.com logoEyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration
finance.yahoo.com - February 3 at 5:39 PM
finance.yahoo.com logoEyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
finance.yahoo.com - January 31 at 9:07 AM
finance.yahoo.com logoEyePoint Pharmaceuticals Inc SVP & Chief Commercial Officer David Jones Sells 26,017 Shares
finance.yahoo.com - January 30 at 1:34 AM
marketbeat.com logoEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Rating of "Buy" from Analysts
marketbeat.com - January 28 at 4:33 AM
finance.yahoo.com logoEyePoint Pharmaceuticals Inc's Chief Medical Officer Dario Paggiarino Sells 16,386 Shares
finance.yahoo.com - January 26 at 11:21 PM
marketbeat.com logoInsider Selling: EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) SVP Sells 600 Shares of Stock
marketbeat.com - January 26 at 7:02 PM
marketbeat.com logoEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Insider Dario A. Paggiarino Sells 5,135 Shares
marketbeat.com - January 25 at 6:57 PM
finance.yahoo.com logoEyePoint Pharmaceuticals Inc SVP & Chief Commercial Officer David Jones Sells 35,066 Shares
finance.yahoo.com - January 24 at 9:26 PM
marketbeat.com logoDavid Scott Jones Sells 900 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Stock
marketbeat.com - January 24 at 7:48 PM
marketbeat.com logo71,800 Shares in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Bought by TD Asset Management Inc
marketbeat.com - January 23 at 5:11 AM
markets.businessinsider.com logoUnveiling 7 Analyst Insights On EyePoint Pharmaceuticals
markets.businessinsider.com - January 22 at 11:39 AM
marketbeat.com logoEyePoint Pharmaceuticals (NASDAQ:EYPT) Now Covered by Analysts at JPMorgan Chase & Co.
marketbeat.com - January 22 at 7:13 AM
marketbeat.com logoEyePoint Pharmaceuticals, Inc. to Post FY2023 Earnings of ($1.89) Per Share, HC Wainwright Forecasts (NASDAQ:EYPT)
marketbeat.com - January 18 at 7:14 AM
marketbeat.com logoEyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Down Following Insider Selling
marketbeat.com - January 17 at 10:18 AM
marketbeat.com logoYe Liu Sells 1,910,500 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Stock
marketbeat.com - January 16 at 6:46 PM
marketbeat.com logoHC Wainwright Trims EyePoint Pharmaceuticals (NASDAQ:EYPT) Target Price to $33.00
marketbeat.com - January 16 at 4:24 PM
finance.yahoo.com logoEyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Intrinsic Value Is Potentially 71% Above Its Share Price
finance.yahoo.com - January 14 at 12:55 PM
marketbeat.com logoEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 4.2% After Insider Buying Activity
marketbeat.com - January 12 at 11:20 AM
finance.yahoo.com logoEyePoint Pharmaceuticals Inc's Chief Medical Officer Dario Paggiarino Sells 22,913 Shares
finance.yahoo.com - January 12 at 8:57 AM
marketbeat.com logoEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Major Shareholder Cormorant Asset Management, Lp Buys 105,000 Shares
marketbeat.com - January 11 at 6:37 PM
marketbeat.com logoInsider Selling: EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Insider Sells 22,913 Shares of Stock
marketbeat.com - January 10 at 6:36 PM
finance.yahoo.com logoEyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 VERONA Clinical Trial of EYP-1901 for the Treatment of Diabetic Macular Edema
finance.yahoo.com - January 10 at 8:51 AM
Get EyePoint Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter.



EYPT Media Mentions By Week

EYPT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

EYPT
News Sentiment

0.85

0.61

Average
Medical
News Sentiment

EYPT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

EYPT Articles
This Week

8

3

EYPT Articles
Average Week

Get EyePoint Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:EYPT) was last updated on 3/1/2024 by MarketBeat.com Staff